Overview
A dose of gamma rays from Elekta won't turn you into the Incredible Hulk, but it could make you feel like him. The company manufactures the Gamma Knife -- which isn't a knife at all but a chamber that delivers radiation therapy to treat tumors and cancer in the brain. The Gamma Knife was invented in 1968 by Elekta's founder, Dr. Lars Leksell, the father of radiosurgery. Elekta manufactures other non-invasive treatment systems, such as image-guided
...
Read More radiation therapy (IRGT) and particle therapy, used to treat cancer elsewhere in the body. Elekta was founded in 1972. Its products are used in more than 5,000 hospitals around the world.
Read Less
Read More radiation therapy (IRGT) and particle therapy, used to treat cancer elsewhere in the body. Elekta was founded in 1972. Its products are used in more than 5,000 hospitals around the world.
Read Less
Clas Jonas Bolander
See more contacts
Business Support Services
,
Administrative and Support Services
,
Administrative and Support and Waste Management and Remediation Services
,
Business services, nec
Employment Services
,
Facilities Support Services
,
Investigation and Security Services
,
Office Administrative Services
,
Other Support Services
,
Remediation and Other Waste Management Services
,
Services to Buildings and Dwellings
,
Travel Arrangement and Reservation Services
View more , Waste Collection Waste Treatment and Disposal
View fewer
View more , Waste Collection Waste Treatment and Disposal
View fewer
?
?
Actual
$1.71 billion
Actual
7.41%
38.07%
$31,413
APR
?
OMXStk:EKTA B
Contacts
Get in Touch with 15 Principals*
-
Clas Jonas BolanderManager
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of April 30, 2024 (12 month period) in USD
Annual Revenue 2024
$1.71 billion
USD
Actual
1 USD = 10.5808 SEK
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $233 | $186 | $176 |
| Net Investing Cash | -$182 | -$153 | -$156 |
| Net Financing Cash | -$104 | -$12 | -$163 |
| Net Change in Cash | -$53 | $21 | -$143 |
| Cash at Beginning of Period | $310 | $291 | $417 |
| Cash at End of Period | $263 | $310 | $291 |
| Capital Expenditure | -$155 | -$148 | -$133 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $262 | $309 | $290 |
| Accounts Receivable | $366 | $377 | $345 |
| Inventories | $308 | $290 | $239 |
| Other Current Assets | $383 | $382 | $343 |
| Asset Summary | |||
| Total Current Assets | $1,319 | $1,359 | $1,217 |
| Tangible Fixed Assets | $210 | $166 | $182 |
| Intangible Assets | $553 | $452 | $356 |
| Total Assets | $31,413 | $29,608 | $26,303 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $146 | $171 | $128 |
| Short-Term Debt | $106 | $1 | $48 |
| Other Current Liabilities | $1,070 | $1,029 | $916 |
| Liability Summary | |||
| Total Current Liabilities | $1,323 | $1,201 | $1,092 |
| Long-Term Debt | $454 | $539 | $387 |
| Other Long-Term Liabilities | $8 | $4 | $11 |
| Total Liabilities | $1,950 | $1,878 | $1,643 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $18 | $18 | $18 |
| Retained Earnings | $691 | $653 | $651 |
| Equity Summary | |||
| Total Equity | $1,018 | $919 | $842 |
| Shares Outstanding | 382,083,120 | 382,083,120 | 382,083,120 |